InMed Pharmaceuticals Inc (INM)

[aparatchik]

I’m hoping for ADR’s on NASDAQ, not a Canadian uplist.

Why: GW pharma currently has a $3.5B market cap on revenue of approximately $10-12M annual and have been burning cash heavily. Even more interesting, at this point 80+% of GW’s share are institutionally owned.

Considering Inmed has significant diversification advantages in revenue pipelines, it’s not difficult to see how they’re well positioned for a sharp uptick based on positive news on a multitude of vectors. I also believe it can absorb a reasonable (not a catastrophic) disappointment in any of their potential rev buckets without being completely derailed.

At a share price under $2, a market cap of $230M and trading on the OTC, Inmed still below the radar for US institutional investors. For a variety of reasons they can’t/won’t touch it yet... enabling them is a key to unlocking exponential sharecorice growth.